Immediate Impact
55 standout
Citing Papers
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Works of Y.S. Park being referenced
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Y.S. Park | 111 | 70 | 80 | 12 | 143 | |
| Claire Hobbs | 99 | 73 | 145 | 8 | 166 | |
| David Alan Anthoney | 126 | 110 | 135 | 9 | 184 | |
| Stefania Eufemia Lutrino | 130 | 65 | 42 | 18 | 185 | |
| Christof Weitzel | 162 | 43 | 54 | 8 | 195 | |
| Enxiao Li | 100 | 54 | 47 | 11 | 150 | |
| Elodie Gaignard | 108 | 127 | 61 | 13 | 179 | |
| Miki Scaravaglio | 62 | 54 | 86 | 10 | 158 | |
| Kento Misumi | 97 | 77 | 157 | 11 | 196 | |
| Ichiro Iwanaga | 126 | 141 | 50 | 17 | 198 | |
| Do-Youn Oh | 150 | 43 | 103 | 11 | 177 |
All Works
Loading papers...